Research Updates
Survivin siRNA Delivery via Exosomes
Learn More
Luciferase siRNA Delivery via Exosomes
Learn More
Custom siRNA Delivery Via Exosomes
Learn More
For Investors
Advantages of RNA Nanoparticles for Therapy
Negative charge disallows nonspecific permeation of negatively charged cell membrane
Controlled synthesis provides defined structure and stoichiometry
Multi-valency allows combination therapy and simultaneous targeting and detection
Targeted delivery allows receptor mediated endocytosis
Advantageous size (10 – 40 nm)
Extended in vivo half-life (5-12 hr compared to 15-45 min for siRNA)
Avoidance of antibody induction (protein-free) allows repeated treatment for chronic diseases
- Favorable pharmacokinetic profile in mice:
Half-life (T1/2) : 5-10 hr compared to 0.25-0.76 hr of siRNA counterpart;
Clearance (Cl): <0.13 l/kg/hr,
Volume of distribution (V(d)): 1.2 l/kg;
Does not induce interferon (IFN) response or cytokine productionï¼›
Repeated IV administrations of up to 30 mg/kg do not result in toxicity.
- RNA nanoparticles are classified as chemical drugs rather than biologics. This classification facilitates drug approval.